Pharma BD Deal Intelligence
Roche paid $600M to lock down clean ECL patent title and end a decade of IGEN litigation — instead it inherited a new decade-plus lawsuit (Meso Scale Diagnostics) over the very same IP, with a $137M willful-infringement verdict still being litigated 15+ years later.
Full analysis, sources & comparables →Roche to acquire BioVeris for $21.50 per share in cash, approximately $600 million, giving Roche the complete patent estate of the electrochemiluminescence…
Roche strikes $600M deal to buy BioVeris, securing the full patent estate behind the ECL technology that powers its Elecsys immunodiagnostics franchise and…
Roche CEO described ECL as 'a highly innovative technology' offering enhanced sensitivity, short incubation times, and broad measuring ranges; acquisition…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
$21.50/share, ~$600M. Closed June 2007. Electrochemiluminescence (ECL) diagnostics IP. Source: BioSpace, Technology Networks.
Roche paid $600M to lock down clean ECL patent title and end a decade of IGEN litigation — instead it inherited a new decade-plus lawsuit (Meso Scale Diagnostics) over the very same IP, with a $137M willful-infringement verdict still being litigated 15+ years later.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / BioVeris Corporation (this deal) | 2007 | $600M | 54 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2007 deals · Roche Holding AG deals